Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Miragen Therapeutics, Inc is a biotechnology business based in the US. Miragen Therapeutics shares (MGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Miragen Therapeutics employs 45 staff and has a trailing 12-month revenue of around USD$1.9 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$18.03 |
---|---|
52-week range | USD$4.665 - USD$34.05 |
50-day moving average | USD$15.4053 |
200-day moving average | USD$14.5705 |
Wall St. target price | USD$40 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.291 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $18.03 from 2020-12-09
1 week (2021-01-11) | -17.78% |
---|---|
1 month (2020-12-18) | -9.62% |
3 months (2020-10-16) | 3,178.18% |
6 months (2020-07-17) | 1,600.94% |
1 year (2020-01-17) | 2,631.82% |
---|---|
2 years (2019-01-18) | 497.02% |
3 years (2018-01-18) | 127.65% |
5 years (2016-01-15) | 2,673.85% |
Revenue TTM | USD$1.9 million |
---|---|
Gross profit TTM | USD$-28,633,000 |
Return on assets TTM | -48.09% |
Return on equity TTM | -136.12% |
Profit margin | 0% |
Book value | $5.53 |
Market capitalisation | USD$65.4 million |
TTM: trailing 12 months
There are currently 152,113 Miragen Therapeutics shares held short by investors – that's known as Miragen Therapeutics's "short interest". This figure is 63.2% down from 413,381 last month.
There are a few different ways that this level of interest in shorting Miragen Therapeutics shares can be evaluated.
Miragen Therapeutics's "short interest ratio" (SIR) is the quantity of Miragen Therapeutics shares currently shorted divided by the average quantity of Miragen Therapeutics shares traded daily (recently around 1.0 million). Miragen Therapeutics's SIR currently stands at 0.15. In other words for every 100,000 Miragen Therapeutics shares traded daily on the market, roughly 150 shares are currently held short.
However Miragen Therapeutics's short interest can also be evaluated against the total number of Miragen Therapeutics shares, or, against the total number of tradable Miragen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Miragen Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Miragen Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0391% of the tradable shares (for every 100,000 tradable Miragen Therapeutics shares, roughly 39 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Miragen Therapeutics.
Find out more about how you can short Miragen Therapeutics stock.
We're not expecting Miragen Therapeutics to pay a dividend over the next 12 months.
Miragen Therapeutics's shares were split on a 1:15 basis on 13 November 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Miragen Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Miragen Therapeutics shares which in turn could have impacted Miragen Therapeutics's share price.
Over the last 12 months, Miragen Therapeutics's shares have ranged in value from as little as $4.665 up to $34.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Miragen Therapeutics's is 1.349. This would suggest that Miragen Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Steps to owning and managing DRIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing CYBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHCI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CKX, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTHR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CNBKA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CATM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRME, with 24-hour and historical pricing before you buy.